News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.1 The topline findings will also be presented in a late-breaking poster session at the American Society of Nephrology (ASN) Kidney Week meeting in Philadelphia, PA.
This Family Health History Month, five-time Olympic gold medalist Missy Franklin is teaming up with Otsuka to shine a light on the importance of initiating family conversations about health history – particularly in those with a history of kidney disease. Through this ongoing collaboration, Missy is sharing how autosomal dominant polycystic kidney disease (ADPKD) has affected her own family. ADPKD is a rare genetic condition that causes cysts to form on the kidneys, eventually leading to a decline in kidney function and requiring a need for dialysis or a transplant.
Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD). Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor.
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced results from two Phase 3 clinical trials of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).